Ibogaine for Depression,
OCD & Traumatic Brain Injury

The analytics dashboard below presents aggregated outcome trajectories for all 58 patients across four validated scales. PHQ-9 (depression), GAD-7 (anxiety), Y-BOCS (OCD), and a composite TBI cognitive recovery score. providing a unified view of ibogaine's therapeutic reach across this multi-condition cohort. These three conditions are rarely grouped in the same study, but their inclusion here is methodologically deliberate: depression, OCD, and TBI all involve pathological rigidity in neural circuit function, and tracking their responses to a shared neuroplasticity-based intervention reveals whether the therapeutic mechanism is condition-specific or operates at a more fundamental neurobiological level.

Ibogaine's BDNF and GDNF upregulation, sigma-1 receptor agonism, and temporary disruption of pathological default mode network activity create a window of enhanced neural flexibility that operates across this entire diagnostic spectrum. In depression, this disrupts self-referential rumination loops anchored in the default mode network. In OCD, it interrupts the cortico-striato-thalamo-cortical hyperdrive that sustains compulsive cycles. In TBI, it modulates post-concussive neuroinflammation and promotes axonal repair processes. The dashboard captures whether these parallel mechanisms produce measurable improvement in the same patient population within the same treatment window.

The trajectory data reveals a pattern that is mechanistically coherent: depression, OCD, and cognitive recovery scores improve in parallel across the treatment timeline, with the sharpest gains occurring in the 3 to 7 days following ibogaine administration. the period during which BDNF upregulation and default mode network reorganization are most active. This temporal clustering of improvement across three clinically distinct conditions, all within the same pharmacological window, is strong evidence that the therapeutic mechanism is not condition-specific but rather operates at the level of fundamental neural circuit plasticity.

The comorbid subgroup. patients carrying TBI alongside depression or OCD, showed compound response rates that exceeded the single-condition averages, suggesting that the neuroinflammatory burden in TBI was independently amplifying the depressive and obsessive-compulsive circuitry dysfunction, and that ibogaine's anti-neuroinflammatory properties addressed this compounding effect directly. Resolving the TBI-driven neuroinflammatory cascade appeared to accelerate the depression and OCD therapeutic response rather than competing with it.

The following chart examines depression and anxiety outcomes in granular detail, presenting baseline and post-treatment scores on two of psychiatry's most widely validated self-report instruments. The PHQ-9 (Patient Health Questionnaire-9) measures depression severity on a 0 to 27 scale: scores of 15 and above indicate moderately severe depression, while scores of 20 or above indicate severe depression. A cohort average of 21 at baseline confirms that this population represented genuinely severe, treatment-resistant cases, not mild or moderate presentations that might respond to any intervention. The GAD-7 (Generalized Anxiety Disorder 7-item scale) measures anxiety severity from 0 to 21, with scores above 15 indicating severe anxiety.

The co-occurrence of severe depression and anxiety in this cohort is clinically typical: GAD-7 scores averaging 17 at baseline reflect the anxious rumination that frequently accompanies and amplifies treatment-resistant depressive disorder. Ibogaine's simultaneous action on both the serotonergic and default mode network pathways driving these presentations makes it a particularly rational intervention for comorbid depression-anxiety. a profile that often requires multiple medications and years of therapy under conventional approaches.

The depression and anxiety reductions documented above represent the affective and ruminative dimensions of neuropsychiatric dysfunction. the subjective suffering layer. The following chart shifts to the structural and behavioral dimensions: OCD symptom severity and cognitive recovery in TBI, both of which involve circuit-level disruptions that standard antidepressants and anxiolytics do not address. PHQ-9 and GAD-7 improvements, while substantial, tell only part of the neuroplasticity story. the Y-BOCS and TBI cognitive scores reveal whether ibogaine's circuit-remodeling effects penetrate into the deeper structural dysfunction underlying obsessive-compulsive and post-concussive presentations.

The mechanism connecting depression-anxiety improvement to OCD and TBI recovery is not coincidental. it is the shared neuroplasticity pathway. Once BDNF upregulation and default mode network reorganization create the window of neural flexibility observed in the depression-anxiety outcomes, the same biological conditions that allowed affective circuit reconfiguration are simultaneously available to the cortico-striato-thalamo-cortical loops in OCD and the axonal repair processes in TBI. This is why multi-condition improvement within a single treatment window is not only possible but mechanistically expected.

Taken together across both charts, the four-metric outcome profile tells a coherent story about ibogaine's breadth of action. PHQ-9 dropping from 21 to 8 represents a categorical shift from severe depression to mild symptom burden, moving patients across a clinically meaningful threshold that most pharmacological interventions achieve only after months of titration. Y-BOCS declining from 28 to 12 moves the OCD subgroup from the severe range into mild-to-moderate territory, where the subjective experience of obsessional intrusion and compulsive drive is meaningfully reduced rather than simply diminished.

The TBI cognitive composite doubling from 4 to 8. a 100% improvement in the proxy score, is perhaps the most striking finding in the dataset, because it occurs in a population for whom no currently approved treatment produces cognitive recovery of this magnitude. Standard TBI rehabilitation focuses on compensatory strategies and symptom management; ibogaine appears to operate at the level of neural substrate repair through anti-neuroinflammatory and neurotrophic mechanisms that address the underlying injury pathophysiology. The convergence of meaningful improvement across all four metrics, depression, anxiety, OCD, and TBI cognition, within a single 14-day treatment protocol constitutes the strongest evidence in this study for ibogaine's fundamental neuroplasticity mechanism rather than any condition-specific pharmacological action.